Glaxosmithkline Share News (GSK)

IN BRIEF: De La Rue shares up new CFO Charles Andrews appointed

De La Rue PLC - Basingstoke, England-based security printed products maker - Hires Charles Andrews as interim chief financial officer, with effect from April 11. This follows the resignation of Rob Harding in January, who left to become CFO at payment services provider PayPoint PLC. Most recently, Andrews was senior vice president Airframe at aerospace firm Meggitt PLC, and has held senior finance roles at Ingram Micro Inc and GSK PLC.

LONDON MARKET CLOSE: Risk-off mood prevails but FTSE 100 outperforms

(Alliance News) - Stocks in London closed largely lower on Wednesday, while the FTSE 100 ended in the green thanks to a solid performance from utility and pharmaceutical stocks.

World making 'huge mistake' not funding new TB vaccines - Gates

LONDON, April 4 (Reuters) - A lack of funding could delay late-stage trials of the first new vaccine against tuberculosis for more than a century, warned Bill Gates, whose foundation is backing the development of the shot.

London stocks close out quarter higher as healthcare, consumer stocks gain

U.S. consumer spending falls in Feb

*

U.S. judge blocks Obamacare coverage mandate for some cancer screenings, PrEP

March 30 (Reuters) - A federal judge in Texas on Thursday blocked Obamacare's mandate that health insurance plans cover preventive care, including screenings for certain cancers and pre-exposure prophylaxis against HIV (PrEP), at no cost to patients.

GSK licenses companies to make cheap copies of HIV prevention drug

LONDON, March 30 (Reuters) - British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new cases occur.

Texas judge blocks Obamacare coverage mandate for PrEP, cancer screening

March 30 (Reuters) - A federal judge in Texas on Thursday blocked Obamacare's mandate that health insurance plans cover pre-exposure prophylaxis against HIV (PrEP) and other preventive care including cancer and diabetes screenings.

GSK licenses companies to make cheap copies of HIV prevention drug

LONDON, March 30 (Reuters) - British drugmaker GSK has signed deals with three companies allowing them to make inexpensive generic versions of its long-acting HIV preventive medicine for use in lower-income countries, where the majority of new HIV cases occur.

GSK says RUBY dostarlimab phase 3 trial shows positive results

(Alliance News) - GSK PLC on Tuesday said interim results from the first part of its Ruby phase 3 clinical trial of its dostarlimab treatment in patients with primary advanced or recurrent endometrial cancer have shown positive results.

GSK receives 'positive' results from endometrial cancer drug trial

(Sharecast News) - Pharmaceutical giant GSK revealed on Tuesday that a recent trial on its endometrial cancer drug candidate showed the potential of the medication when used alongside chemotherapy.

Amgen-Sanofi patent case divides makers of antibody drugs

March 27 (Reuters) - Amgen Inc's battle with Sanofi and Regeneron at the U.S. Supreme Court over its cholesterol drug Repatha on Monday has some drugmakers hoping a ruling will reshape U.S. patent law and competition among companies that make antibody medicines.

GSK loses bid to keep experts out of upcoming Zantac trial

March 24 (Reuters) - A California judge on Thursday denied GSK Plc's bid to keep expert testimony linking its discontinued heartburn drug Zantac to cancer out of an upcoming trial, a setback for the British drugmaker facing lawsuits over the medicine in courts across the United States.

GSK disagrees with ranitidine evidence ruling in California

(Sharecast News) - Pharmaceuticals giant GSK responded to a recent ruling in the ongoing legal wranglings over its now-suspended blockbuster heartburn drug Zantac on Friday.

GSK refutes California state court ruling on Zantac's cancer links

(Alliance News) - Pharmaceutical company GSK PLC on Friday said it disagrees with a California state court ruling on Zantac and its links with cancer.

Vaccine makers prep bird flu shot for humans 'just in case'; rich nations lock in supplies

LONDON, March 20 (Reuters) - Some of the world's leading makers of flu vaccines say they could make hundreds of millions of bird flu shots for humans within months if a new strain of avian influenza ever jumps across the species divide.